首页> 美国卫生研究院文献>Disease Markers >Effect of Genetic Variant (rs11887534) in ABCG8 Gene in Coronary Artery Disease and Response to Atorvastatin Therapy
【2h】

Effect of Genetic Variant (rs11887534) in ABCG8 Gene in Coronary Artery Disease and Response to Atorvastatin Therapy

机译:ABCG8基因遗传变异(rs11887534)在冠状动脉疾病中的作用及对阿托伐他汀治疗的反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: ATP-binding cassette transporter ABCG8 plays an important role in excretion of cholesterol from liver. Common genetic polymorphisms in ABCG8 gene may genetically predispose an individual to coronary artery disease (CAD) along with response to atorvastatin therapy. Thus, we aimed to examine the role of ABCG8 D19H polymorphism (rs11887534) in susceptibility to CAD and its influence on atorvastatin response. Methodology: The study included 213 CAD patients and 220 controls. Genotyping of ABCG8 D19H polymorphism was done by PCR-RFLP. Results: Our results showed that ABCG8 ‘H’ allele was conferring significant risk for CAD in a dominant model (OR = 2.54; p = 0.014). This increased risk for CAD was more pronounced in males (OR = 2.69; p = 0.030). No correlation of ABCG8 genotypes with the risk factors (diabetes, hypertension and smoking) of CAD was observed. On atorvastatin treatment there was a significant decrease in the LDL-C levels (p = 0.021). However, stepwise multiple regression analysis showed that this decease was not associated with ABCG8 genetic variant (p = 0.845). Observed determinants of variation in interindividual response to atorvastatin therapy were pre-treatment LDL-C (p = 0.024) and TC (p = 0.017). Conclusion: Although the genetic variant 19H of ABCG8 confers risk for CAD in North Indian population, it is not associated with interindividual response to atorvastatin therapy.
机译:背景:ATP结合盒转运蛋白ABCG8在从肝脏排泄胆固醇中起重要作用。 ABCG8基因中常见的遗传多态性可能会导致个体易患冠状动脉疾病(CAD)以及对阿托伐他汀治疗的反应。因此,我们旨在研究ABCG8 D19H多态性(rs11887534)在CAD易感性及其对阿托伐他汀反应中的影响。方法:该研究包括213名CAD患者和220名对照。通过PCR-RFLP进行ABCG8 D19H多态性的基因分型。结果:我们的结果表明,在显性模型中,ABCG8'H'等位基因具有显着的CAD风险(OR = 2.54; p = 0.014)。男性患CAD的风险增加更为明显(OR = 2.69; p = 0.030)。没有观察到ABCG8基因型与CAD的危险因素(糖尿病,高血压和吸烟)相关。阿托伐他汀治疗后,LDL-C水平显着下降(p = 0.021)。但是,逐步多元回归分析表明,这种死亡与ABCG8遗传变异无关(p = 0.845)。观察到的个体对阿托伐他汀治疗反应差异的决定因素是治疗前的LDL-C(p = 0.024)和TC(p = 0.017)。结论:尽管ABCG8的19H基因变异赋予北印度人群CAD风险,但与个体对阿托伐他汀治疗的反应无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号